Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

168
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
168
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

1.7K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
1.7K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

678
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
678
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

9
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
9
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

560
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
560
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

769
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
769

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic risk score in patients with the APOE2/E2 genotype as a predictor of familial dysbetalipoproteinemia.

Journal of clinical lipidology·2023
Same author

The frequency of, and predisposing risk factors for, ciprofloxacin-induced neuro-psychiatric adverse drug reactions.

Bratislavske lekarske listy·2023
Same author

Cardiovascular risk in myositis patients compared with the general population.

Rheumatology (Oxford, England)·2023
Same author

Low LDL-C goal attainment in patients at very high cardiovascular risk due to lacking observance of the guidelines on dyslipidaemias.

PloS one·2023
Same author

Cardiovascular Risk in Myositis Patients Compared to the General Population: Preliminary Data From a Single-Center Cross-Sectional Study.

Frontiers in medicine·2022
Same author

PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology.

Current atherosclerosis reports·2022

Related Experiment Video

Updated: Jul 13, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Dyslipidemia - the known unknown.

Martin Šatný

    Vnitrni Lekarstvi
    |October 12, 2023
    PubMed
    Summary

    Dyslipidemia (DLP) significantly increases risks for atherosclerotic cardiovascular disease (ASCVD) and acute pancreatitis. Current DLP management, especially in high-risk individuals, requires improvement, with new therapies like inclisiran offering enhanced adherence.

    Area of Science:

    • Cardiology
    • Endocrinology
    • Metabolic Diseases

    Background:

    • Dyslipidemia (DLP) is a primary risk factor for atherosclerotic cardiovascular disease (ASCVD) and acute pancreatitis, particularly with severe hypertriglyceridemia.
    • High prevalence of DLP contrasts with inadequate control, especially in high-risk populations.
    • Secondary causes of DLP must be excluded during diagnosis.

    Purpose of the Study:

    • To outline current strategies for managing dyslipidemia (DLP).
    • To emphasize risk stratification and individualized lipid target setting for ASCVD prevention.
    • To introduce novel therapeutic options for dyslipidemia management.

    Main Methods:

    • Assessment of overall cardiovascular (CV) risk using SCORE2/SCORE2-OP or individual comorbidities.
    Keywords:
    acute pancreatitisacute pancreatitsatherosclerotic cardiovascular diseasecardiovascular riskcombination therapydyslipidemiainclisiran

    More Related Videos

    Assessing Whole-Body Lipid-Handling Capacity in Mice
    07:57

    Assessing Whole-Body Lipid-Handling Capacity in Mice

    Published on: November 24, 2020

    4.0K
    Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
    07:29

    Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

    Published on: October 12, 2017

    9.3K

    Related Experiment Videos

    Last Updated: Jul 13, 2025

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
    09:15

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

    Published on: November 10, 2017

    14.7K
    Assessing Whole-Body Lipid-Handling Capacity in Mice
    07:57

    Assessing Whole-Body Lipid-Handling Capacity in Mice

    Published on: November 24, 2020

    4.0K
    Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
    07:29

    Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

    Published on: October 12, 2017

    9.3K
  • Implementation of dietary and lifestyle modifications as first-line treatment.
  • Pharmacological interventions including statins, ezetimibe, PCSK9 inhibitors (inclisiran), and specific agents for severe hypertriglyceridemia (fibrates, lomitapide, volanesorsen, evinacumab).

    • Main Results:

    • Target lipid values, particularly LDL-cholesterol, are determined by CV risk category.
    • Inclisiran, a novel siRNA targeting PCSK9, offers improved adherence when administered in outpatient clinics.
    • For severe hypertriglyceridemia, fibrates are a primary option, with other specialized therapies available under strict criteria.

    Conclusions:

    • Effective dyslipidemia management is crucial for preventing ASCVD and pancreatitis.
    • A multi-faceted approach combining lifestyle changes, risk assessment, and tailored pharmacotherapy is essential.
    • Newer agents like inclisiran represent advancements in DLP treatment, improving patient adherence and outcomes.